Evidence map›Paper›PMID 39191899›Full record

ArticleScientific reports2024

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.

Sijin Chen, Dewen Zhong, Chenbo Yu, Desheng Cai, Qichen Wei, Minggen Yang, Tao Li, Qingguo Zhu, Liefu Ye, Yongbao Wei and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sijin Chen *Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Hunan Province, Changsha, 410005, People's Republic of China.
Dewen ZhongDepartment of Urology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, People's Republic of China.
Chenbo YuShengli Clinical Medical College of Fujian Medical University, No.134, Dong Street, Fuzhou, 350001, People's Republic of China.
Desheng CaiShengli Clinical Medical College of Fujian Medical University, No.134, Dong Street, Fuzhou, 350001, People's Republic of China.
Qichen Wei *Department of Urology, Gutian County Hospital, Ningde, 352200, People's Republic of China.
Minggen YangDepartment of Urology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, People's Republic of China.
Tao LiShengli Clinical Medical College of Fujian Medical University, No.134, Dong Street, Fuzhou, 350001, People's Republic of China.
Qingguo ZhuShengli Clinical Medical College of Fujian Medical University, No.134, Dong Street, Fuzhou, 350001, People's Republic of China.
Liefu YeShengli Clinical Medical College of Fujian Medical University, No.134, Dong Street, Fuzhou, 350001, People's Republic of China.
Yongbao WeiShengli Clinical Medical College of Fujian Medical University, No.134, Dong Street, Fuzhou, 350001, People's Republic of China. weiyb@fjmu.edu.cn.
Jinfeng WuShengli Clinical Medical College of Fujian Medical University, No.134, Dong Street, Fuzhou, 350001, People's Republic of China. 32252641@qq.com.

Funding

Health Commission of Hunan Province B202304056664
6 · The paper itself

Abstract

Although overall survival data are still premature, the PROpel study found radiological progression-free survival (PFS) benefits of abiraterone and olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). However, for patients who have not been genetically tested or lack BRCA1/2 mutations (BRCAm), this combination therapy has been questioned as a first-line conventional treatment for mCRPC, mainly due to significant health economics and side effects. In our retrospective study, we found that treatment with low-dose abiraterone plus olaparib as a late-line treatment for mCRPC could lead to prostate-specific antigen (PSA) and symptom PFS in selective cases even without BRCAm. The median PSA-PFS was 8 months (IQR: 6.5-11.5), with a median follow-up duration of 39.0 months (IQR: 27.5-64.5). Gene tests were conducted in all patients, identifying non-BRCA mutations through ctDNA testing (24%), tumor tissue testing (12%), or both (64%). Adverse events occurred in 72% of patients, with 16% experiencing Grade ≥ 3 events. Common adverse events included anemia (64%), decreased appetite (48%), and fatigue (25%). Our findings support low-dose abiraterone plus olaparib as a potential option for mCRPC patients without BRCAm, offering manageable safety and efficacy profiles.

Indexed as

AndrostenesAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinPhthalazinesPiperazinesProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedMutationPilot ProjectsProgression-Free SurvivalProstate-Specific AntigenabirateroneAndrostenesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanolaparibPhthalazinesPiperazinesProstate-Specific AntigenAbirateroneBRCA1/2 mutationsLate-line treatmentmCRPCOlaparibProstate cancer

Identifiers

PMID39191899
PMCPMC11349984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.